On supporting science journalism
If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.
Nicotine has undergone an image overhaul, at least biomedically. In the past few years researchers have found that the substance can alleviate symptoms of ailments such as Alzheimer's disease and ulcerative colitis. Just how nicotine battles these foes, however, has remained unclear. Now, by studying sepsis, Luis Ulloa of North Shore University Hospital in Manhasset, N.Y., has evidence elucidating nicotine's biochemical pathways that could lead to more potent anti-inflammatory drugs.
Sepsis, the most lethal of inflammatory conditions, is a bacterial invasion of the bloodstream. The third leading cause of death in the developed world, it accounts for nearly 10 percent of overall deaths in the U.S. every year. Infection causes part of the damage, but what makes patients critically ill is their own fiercely aggressive immune response. Macrophages churn out huge quantities of proinflammatory cytokines. This exaggerated immune response leads to tissue damage, and eventually the patient dies of cardiovascular dysfunction and multiorgan failure.
Subscribe to Support Independent Journalism
Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.
When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.
Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber
